SMT201300030B - Uso del pasireotide per il trattamento di ipoglicemia iperinsulinemica endogena - Google Patents

Uso del pasireotide per il trattamento di ipoglicemia iperinsulinemica endogena

Info

Publication number
SMT201300030B
SMT201300030B SM201300030T SM201300030T SMT201300030B SM T201300030 B SMT201300030 B SM T201300030B SM 201300030 T SM201300030 T SM 201300030T SM 201300030 T SM201300030 T SM 201300030T SM T201300030 B SMT201300030 B SM T201300030B
Authority
SM
San Marino
Prior art keywords
pasireotide
treatment
hyperinsulinemic hypoglycemia
endogenous
endogenous hyperinsulinemic
Prior art date
Application number
SM201300030T
Other languages
English (en)
Italian (it)
Inventor
Herbert Schmid
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SMT201300030B publication Critical patent/SMT201300030B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SM201300030T 2008-07-08 2013-03-20 Uso del pasireotide per il trattamento di ipoglicemia iperinsulinemica endogena SMT201300030B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08159918 2008-07-08
PCT/EP2009/058573 WO2010003939A1 (en) 2008-07-08 2009-07-07 Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia

Publications (1)

Publication Number Publication Date
SMT201300030B true SMT201300030B (it) 2013-07-09

Family

ID=39876604

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201300030T SMT201300030B (it) 2008-07-08 2013-03-20 Uso del pasireotide per il trattamento di ipoglicemia iperinsulinemica endogena

Country Status (12)

Country Link
US (2) US9314508B2 (ru)
EP (1) EP2310042B1 (ru)
JP (1) JP5721624B2 (ru)
CY (1) CY1113726T1 (ru)
DK (1) DK2310042T3 (ru)
ES (1) ES2399651T3 (ru)
HR (1) HRP20130145T1 (ru)
PL (1) PL2310042T3 (ru)
PT (1) PT2310042E (ru)
SI (1) SI2310042T1 (ru)
SM (1) SMT201300030B (ru)
WO (1) WO2010003939A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050285A1 (es) * 2003-06-24 2005-06-09 Novartis Ag Composicion farmaceutica que comprende analogos ciclicos de somatostatina
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
JP5127466B2 (ja) 2005-01-21 2013-01-23 カムルス エービー 医薬脂質組成物
EP3456340B1 (en) 2007-01-08 2022-02-16 The Trustees of the University of Pennsylvania Glp-1 receptor antagonist for use in the treatment of congenital hyperinsulinism
MX350964B (es) * 2012-05-25 2017-09-27 Camurus Ab Formulaciones de agonistas del receptor de somatostatina.
WO2016141111A1 (en) * 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
LT3297653T (lt) 2015-05-22 2022-01-10 The Board Of Trustees Of The Leland Stanford Junior University Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
BR112019010236A2 (pt) 2016-11-21 2019-08-20 Eiger Biopharmaceuticals Inc formulações tamponadas de exendina (9-39)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393050A (en) * 1981-04-29 1983-07-12 The Salk Institute For Biological Studies Analogs of extended N-terminal somatostatin
US4703034A (en) * 1986-04-28 1987-10-27 Merck & Co., Inc. Novel cyclic tetrapeptide
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
EP1446137A2 (en) * 2001-11-21 2004-08-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Somatostatin analog and uses thereof
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
WO2005053732A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Biomarkers for the efficacy of somatostatin analogue treatment
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
SI2310042T1 (sl) 2013-03-29
CY1113726T1 (el) 2016-06-22
US20110124555A1 (en) 2011-05-26
JP5721624B2 (ja) 2015-05-20
US20160184388A1 (en) 2016-06-30
PL2310042T3 (pl) 2013-05-31
DK2310042T3 (da) 2013-03-04
US9867864B2 (en) 2018-01-16
WO2010003939A1 (en) 2010-01-14
ES2399651T3 (es) 2013-04-02
HRP20130145T1 (hr) 2013-03-31
ES2399651T8 (es) 2020-11-18
EP2310042B1 (en) 2012-12-05
EP2310042A1 (en) 2011-04-20
JP2011527309A (ja) 2011-10-27
PT2310042E (pt) 2013-03-11
US9314508B2 (en) 2016-04-19

Similar Documents

Publication Publication Date Title
SMT201300030B (it) Uso del pasireotide per il trattamento di ipoglicemia iperinsulinemica endogena
NL300938I2 (nl) Niraparib tosylaat of niraparib tosylaat monohydraat
SMT201400008B (it) Uso di betanecolo per il trattamento di xerostomia
SMT201700006B (it) Analoghi della triazina e uso di essi come agenti terapeutici e sonde diagnostiche
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
DK2242409T3 (da) Engangspumpe med tilbagesugningsmekanisme
SMT201700056B (it) Fosfaplatine e relativo utilizzo per il trattamento di cancro
SMT201400177B (it) Diagnosi e trattamenti di carcinoma basati sul genotipo di odc1
IT1391866B1 (it) Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari.
BRPI0907954A2 (pt) Tratamento de hipertensão com 25-hidroxivitamina d3
DK2237727T3 (da) Vævsretraktor
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
SMT201500086B (it) Uso del nifuratel per il trattamento di infezioni causate dalla specie atopobium
ITMI20080898A1 (it) Uso di batteri probiotici per il trattamento della iperomocisteinemia
CL2008001795A1 (es) Uso de un antagonista par1 en el tratamiento de la fibrilacion atrial.
BRPI0909840A2 (pt) Uso de 4-tio-2-deoxinucleosídios
IT1396812B1 (it) Dispositivo per il trasporto di strumenti medicali.
BRPI0907956A2 (pt) Uso de ranolazina para o tratamento de doenças cardiovasculares
IT1391593B1 (it) Cambretta per sutura dello sterno
ITBO20080072A1 (it) Apparato per il trattamento di materiali di rifiuto
IT1403597B1 (it) Procedimento per il trattamento di materiali tessili
IT1398376B1 (it) Nuove composizioni per il trattamento di leucemie chemioresistenti e/o di leucemie potenzialmente chemioresistenti.
IT1392215B1 (it) Testata per pompe e procedimento per la realizzazione di detta testata